Introduction
Although the global incidence of tuberculosis (TB) has started to fall, after reaching its peak in 2004, the total number of cases and deaths continues to rise as the world's population increases. 1 This is most apparent in Africa where 12% of the world's population carry 28% of the global burden of TB. 1 HIV infection is the most important risk factor for the development of active TB both through reactivation of latent TB and the acquisition of exogenous infection. 2, 3 HIV is thought to be responsible for 8% of all new adult cases of TB worldwide though this is likely to be much higher in Africa where 80% of all TB/HIV co-infections are found. 1 In 2007, TB/HIV killed 380,000 people worldwide. 1 Co-infection with HIV/TB negatively impacts on the outcome of both diseases. Firstly, HIV leads to increased risk of TB infection after exposure followed by a higher rate of progressive primary and subsequently reactivated disease. Furthermore, extrapulmonary and severe disease, such as meningitis, is more frequent. Finally, TB predisposes to high HIV viral loads and increased rates of progression to AIDS. 4, 5 Combination antiretroviral therapy (cART) has been shown to reduce the risk of developing active TB and TB-related mortality. [6] [7] [8] [9] In the UK in 2008, 6 .7% of adults with TB were co-infected with HIV. 10 This level is likely to be higher in cities such as London, with large immigrant populations. HIV testing by TB physicians is vital for the identification of co-infected patients and allows interventions such as co-trimoxazole prophylaxis and the introduction of cART. 11 Despite current efforts, it is estimated that approximately one quarter of the 86,500 people infected with HIV in the UK remain undiagnosed. 12 In 2005, the British HIV Association (BHIVA) published guidance on the management of TB/HIV co-infection. 13 Complementary recommendations have since been released by the National Collaborating Centre for Chronic Conditions (NCCCC) entitled Tuberculosis: clinical diagnosis and management of tuberculosis and measures for its prevention and control. 14 In addition, the Department of Health has released guidance for the control and prevention of TB. 15, 16 This article investigates how current UK management of TB/HIV co-infection meets with recommended practice by way of a national audit. In addition, the results of a national survey of clinical services aimed at determining how local care is arranged for patients with TB/HIV infection are presented.
Methods
Services listed on the BHIVA database and thought to provide adult HIV care were contacted by mail and invited to complete an online survey and review case notes of all HIV positive patients aged over 16 who started therapy for active TB during the period October 2007 to April 2008. These HIV services were also asked to contact their corresponding TB services (if separate) and invite them to complete a similar survey. The survey sought to answer two main questions:
• What are the local care arrangements for TB/HIV coinfected patients?
• What are the local policies for HIV testing in patients with
TB?
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Results

Surveys of HIV and TB services
Responses were received from 124 (73%) of 170 HIV services surveyed, and 18 corresponding TB services. Of the HIV services, 19 (15%) were fully integrated departments with the same clinical team providing care for mono-infected patients with TB or with HIV and for co-infected HIV/TB patients. The remaining 105 non-integrated HIV services reported a variety of arrangements for managing HIV/TB co-infection including liaison between HIV and TB clinicians with each managing their own respective aspects of care (68 HIV services, also reported by 16 of the 18 TB services), management of uncomplicated TB cases by HIV clinicians with referral of more complex cases (10) and joint clinics (6).
The majority of services treating TB cases test patients for HIV routinely unless the patient refuses consent (13 (68%) of 19 integrated services and 10 (56%) of 18 TB services). Some others offer testing selectively to patients considered at risk (Table 1) . Of the 105 non-integrated HIV services, 17 (16%) thought that their local TB service only tested selected patients.
Case note review
Data were obtained on 236 HIV positive patients who started treatment for active TB during October 2007 to April 2008. There were 124 women (52.5%) and 111 men (47%). In one case, gender was not stated. The majority of patients were black African (74.6%) and a large proportion had originated from high TB prevalence countries (84.7%). The most prevalent age group was between 30 and 50 (73.7%), with fewer patients being aged under 30 years (13.6%) or over 50 years (9.8%).
Notification of TB was documented for 85 (36.0%) patients and believed to have been done in a further 113 (47.9%). Six (2.5%) cases had not been notified, including three with sputum smear positive pulmonary TB, and notification status was unknown for 32 (13.6%).
Most patients (185, 78.4%) attended clinic regularly for HIV care, but 21 (8.9%) missed some appointments, six (2.5%) had died and 23 (9.7%) had stopped attending including nine (3.8%) who were lost to follow-up for HIV (the others having left the UK (9) or transferred care (5) The majority of patients (55.5%) were diagnosed with HIV prior to their investigation for TB. However, 42% were diagnosed as part of their investigation for TB or as a direct result of a TB diagnosis (Table 2 ). Most patients, 69.1% (nϭ163) had advanced HIV disease (CD4Ͻ200 cells/μl) around the time of starting TB treatment. Some of this group (nϭ73) were previously diagnosed with HIV, including 41 already on cART, but the majority (nϭ90) were presenting for the first time with advanced HIV (Fig 1) .
Ninety-six patients (40.7%) had pulmonary TB. However, extra-pulmonary disease was prevalent, either in combination with pulmonary disease (17.4%) or as an isolated entity (41.9%).
Most patients (136, 57.6%) had culture-confirmed TB, including 90 of 137 with pulmonary TB (65.7%). A further 32 (13.6%) were diagnosed via positive microscopy for acid-fast bacilli (AFB) in the absence of culture. In 16 (6.8%), diagnosis was reached via positive histology, cytology or nucleic acid amplification tests without culture or AFB microscopy. Of the remaining 52 (22.0%) cases, 29 had at least one positive investigation, eg imaging, tuberculin skin testing or raised lymphocytes in cerebrospinal fluid, 20 were purely presumptive diagnoses and information was missing for three.
Among 60 sputum smear positive cases, the result was received on the same or next day as the sample was taken in 27 (45%) and within two to three days for 10 (16.7%) but took four or more days for 15 (25%), with data unavailable for eight (13.3%).
At the time of auditing 144 patients (61%) had completed TB treatment without interruption and in 51 (21.6%) treatment was still ongoing. Of 12 (5.1%) patients whose therapy was interrupted, three subsequently completed therapy, and four resumed and were still ongoing. Thus after excluding patients still on therapy, 147 (81.2%) of 181 patients were known to have completed TB treatment. The remaining patients left the UK while on treatment (11, 4.7%), transferred their care within the UK (6, 2.5%), died before completion of therapy (6, 2.5%) or were lost to follow up (6, 2.5%). Of nine patients lost to follow up for HIV care, only two completed TB therapy without interruption and in one this was ongoing.
Discussion
TB remains a major public health concern in the UK with over 9,000 new cases in 2009 and over 450 deaths attributable to TB in 2006. 10 These figures indicate that TB rates have once again increased, having remained fairly stable between 2005 and 2008.
In 2005, the chief medical officer (CMO) published an action plan for the control of TB in England, 13 subsequently supported by a toolkit, 16 with the aim of progressively reducing TB rates within both domestic and immigrant populations. Part of the plan revolved around high quality coordinated services for TB diagnosis, treatment and continuing care, including a recommendation supporting joint services for patients co-infected with TB and HIV. However, we found that the dominant mode of care for such patients was liaison between HIV and TB clinicians with each managing their own aspect of care.
A limitation of the study was the poor response from TB services not providing integrated HIV/TB care, which was likely due to the indirect method of their recruitment. While this limits information about their working practice and interaction with HIV services, it is of concern that a substantial proportion of services did not routinely screen TB patients for HIV infection.
The action plan also stressed the importance of patient-centred care especially since the treatment of TB is a long process. This holds particularly true for the HIV/TB co-infected patient Number of paƟents in whom treatment may be much more complex. Patient retention can be difficult, as a disproportionate number of people with TB have chaotic social circumstances. The case note review found that the majority of co-infected patients attend HIV clinics on a regular basis. However, a small but significant number of patients stopped attending and data suggest a reciprocal relationship between non-attendance for HIV care and non-completion or poor adherence to TB treatment. Similar 'difficult to reach groups' have been identified in previous BHIVA audits. They present a significant challenge as they not only pose a risk to themselves but also to the wider community both from a public health and financial perspective. The plan calls for continued high quality surveillance to help identify outbreaks, monitor trends, inform policy and monitor the success of the TB programme, which includes the statutory requirement for notification of TB cases. Six out of the 236 audited patients had not been notified and, of these, half had sputum smear positive pulmonary TB. Notification was clearly recorded for only a third of patients, although for some sites this may reflect audit completion using HIV notes without access to TB notes or the use of an electronic notification system. Laboratory reporting of culture-confirmed cases became a requirement in October 2010, while the Health Protection Agency has introduced a web-based enhanced TB surveillance reporting system which aims to improve the completeness, accuracy and accessibility of information. Clearly this needs to be implemented together with increased communication between TB and HIV services.
In association with the British Infection Society and the British Association for Sexual Health and HIV, the British HIV Association published national guidelines on HIV testing in 2008, recognising both the public health impact of undiagnosed HIV infection and the role of HIV co-infection as a risk factor and poor prognostic indicator in TB. These state that HIV testing should be routinely recommended to patients with TB, regardless of perceived risk and on an opt-out basis (where the test is done unless the patient refuses). This study illustrates the importance of HIV screening since a high number of patients were diagnosed with HIV as part of their TB investigations. Disappointingly, many services do not routinely offer HIV testing to all TB patients. This audit did not cover TB patients not known to have HIV but, alarmingly, a separate study found that in 2003-4 over half of TB patients in London were not offered HIV testing. Even among those at highest risk, testing was not universally offered. The overall prevalence of HIV was 9.9% and only 27% of those offered testing refused. 17 Although the majority of patients had advanced disease/AIDS (CD4Ͻ200), more than half of these had not been diagnosed with HIV until they sought care for their TB. This reinforces the fact that a significant proportion of the HIV positive population remains undiagnosed and will potentially present for healthcare with advanced immunosuppression. Clinicians, trusts and commissioners should work together to promote HIV testing in all healthcare settings and reduce the proportion of patients with undiagnosed infection, to benefit both individuals and public health in accordance with guidelines and the CMO's advice. Specifically, commissioners should require universal HIV testing as a key quality indicator for TB services.
It is also of concern that a number of sites in this survey showed unacceptable delays in sputum smear results. The HPA states that laboratories should provide a six-day service during the normal working day for smear examination of appropriate samples, with reporting of positive sputum results within 24 hours. All NHS trusts should require laboratories to comply with this standard. Clinicians should consider conducting further local audits of time to receive these results.
According to the CMO's action plan, TB control is likely to be achieved if patients with suspected TB are seen by a specialist team within two weeks of initial presentation -at least 65% of pulmonary TB diagnoses are confirmed by laboratory culture of the organism, and treatment outcomes are recorded for all patients with diagnosed TB with at least 85% completing successfully. Culture is necessary for checking sensitivity to standard treatment regimes, and in this case note review 65.7% of patients with pulmonary TB were culture confirmed thus achieving this target. However, after excluding patients still on treatment, the TB treatment completion rate was 81.2%. Even if all patients who transferred their care within the UK were assumed to have completed, the target of 85% would not have been reached. TB treatment centres should continue to monitor and seek to maximise treatment completion rates.
In conclusion, HIV and TB services should provide high quality, coordinated services for the diagnosis, treatment and continuing care of patients. This service must also strive to meet the needs of the individual including those who attend or adhere poorly for TB and/or HIV care.
